Search
Jan 10, 2023
Stéphane Bancel discusses Moderna's personalized cancer vaccine at #JPM23
Moderna CEO Stéphane Bancel discusses his company's personalized cancer vaccine on Day Two of #JPM23 in San Francisco.
Jan 10, 2023
Rachel Haurwitz on allo CAR-T at #JPM23
Caribou Biosciences's CEO Rachel Haurwitz talks about her company's allogeneic CD19 CAR-T program that has a PD-1 knockout.
Jan 10, 2023
Kite Pharma's Kristi Shaw talks cell therapy at #JPM23
Kite’s Kristi Shaw discusses BCMA, moving CAR-T into earlier lines of treatment, and focusing on improving auto programs.
Jan 10, 2023
BeiGene on BTK Inhibitors and the Inflation Reduction Act.
John Oyler discusses BeiGene's BTK inhibitor Brukinsa and cautions about the Inflation Reduction Act.
Jan 9, 2023
TCR therapies as a new modality in cancer treatment
Immunocore's Bahija Jallal talks about TCR based therapies at #JPM23.
Jan 9, 2023
Beam's Therapeutics' John Evans talks base editing at #JPM23
John Evans talks about base editing as a tool for genetic diseases and cell therapy engineering.
Jun 21, 2022
Noubar Afeyan on Moderna and Biotech Innovation
Flagship Pioneering's Noubar Afeyan describes what it was like to navigate the pandemic as Chairman of Moderna.
.png){kind=logo}
